Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma

Multiple Cancer Types

A Three-Arm Study of ME-401 in Subjects with Relapsed / Refractory CLL / SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL
Leukemia, Lymphoma
I
Reddy, Nishitha
NCT02914938
VICCHEM1714

Prospective Observational Trial of Low-Dose Skin Electron Therapy in Mycosis Fungoides
Using Rotisserie Technique

Lymphoma

Lymphoma
N/A
Kirschner, Austin
NCT02702310
VICCRAD1633

Ibrutinib in Treating Patients with Refractory or Relapsed Lymphoma after Donor Stem Cell Transplant

Multiple Cancer Types

This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Leukemia, Lymphoma
II
Jagasia, Madan
NCT02869633
VICCBMT1651

Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed / Refractory Diffuse Large B Cell Lymphoma

Lymphoma

The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed / refractory diffuse large B-cell lymphoma (DLBCL).
Lymphoma
III
Oluwole, Olalekan
NCT03391466
VICCBMT17102

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma

This study will enroll approximately 160 adult subjects who have relapsed or refractory (r / r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.
Lymphoma
II
Oluwole, Olalekan
NCT03105336
VICCBMT1844

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: